恩替卡韦联合强肝片治疗乙肝肝硬化的临床效果观察

陈保生

（北京大学首钢医院，北京，100014）

中图分类号：R256.42       文献标识码：A    文章编号：1674-7860（2016）18-0085-03   证型：IDGB

【摘  要】目的：探讨恩替卡韦联合强肝片治疗乙肝肝硬化的临床效果。方法：研究我院2014年6月—2015年12月收治的80例乙肝肝硬化患者，分为对照组和观察组各40例，其中对照组运用强肝片治疗，观察组运用恩替卡韦联合强肝片治疗，分析两组治疗效果差异。结果：在治疗总有效率上，观察组为95%，对照组为82.5%，两组差异具有统计学意义，P＜0.05；在治疗后肝功能、Child-Pugh评分、HBV-DNA和纤维环指标上，观察组改善幅度要高于对照组，两组差异具有统计学意义，P＜0.05。结论：恩替卡韦联合强肝片治疗乙肝肝硬化可以有效提升治疗疗效，改善相关机体功能指标，患者满意度高，值得临床广泛推广。

【关键词】恩替卡韦；强肝片；乙肝肝硬化；治疗效果

【Abstract】 Objective:Toexplore the clinical effect of Entecavir combined with Qianggan tablets intreating Hepatitis B liver cirrhosis. Methods: 80 patients with hepatitis B livercirrhosis, admitted to and treated in our hospital from June 2014 to December2015, were divided into the control group and the observation group, with 40cases in each group, the control group received Qianggan tablets while theobservation group received Entecavir combined with Qianggan tablets, the differenceof therapeutic effects of two groups was analyzed. Results:As for the total effective rate, the observation group was 95%while that of the control group was 82.5%, the difference was statisticallysignificant, P<0.05; aftertreatment, the improvement of the liver function, Child-Pugh score, HBV-DNA andannulus index of the observation group was higher than that of the controlgroup, the difference was statistically significant, P<0.05. Conclusion: Entecavir combined with Qianggan tabletscould enhance treatment efficacy effectively in treating Hepatitis B livercirrhosis, it could improve related body function indicators and the patientssatisfaction, and was worthy of clinical promotion.

【Keywords】Entecavir; Qianggan tablets; Hepatitis B liver cirrhosis;Therapeutic effect

doi:10.3969/j.issn.1674-7860.2016.18.040